Pharmacodynamics and Receptor Theory — MCQs

10 questions

A partial agonist has:

In isolated intestinal smooth muscle preparations, drug X binds to cholinergic receptors and causes relaxation. In the absence of drug X, acetylcholine binds to the same receptors and causes contraction. At low concentrations of drug X, the efficacy (Emax) of acetylcholine is decreased, but its potency (EC50) remains unchanged. At high concentrations of drug X, acetylcholine has no effect. Which of the following statements about drug X is true?

Which of the following statements is correct regarding the given graph?

Which of the following is an example of a prodrug?

What is the classification of Buprenorphine in terms of its action on opioid receptors?

Therapeutic drug monitoring is done for:

What does the term 'tolerance' refer to in pharmacology?

In the mitogen activated protein kinase pathway, the activation of RAS is counteracted by

What do A and B represent in the curve shown below?

Q10

Capsaicin acts on ______

Pharmacodynamics and Receptor Theory Indian Medical PG Practice Questions and MCQs

Question 1: A partial agonist has:

A. High affinity with low intrinsic activity (Correct Answer)
B. High affinity with no intrinsic activity
C. Low affinity with high intrinsic activity
D. Low affinity with low intrinsic activity

Explanation: ***High affinity with low intrinsic activity*** - A **partial agonist** binds to the receptor with **high affinity** [1] but elicits a submaximal response, indicating partial activation [1],[2]. - Its **intrinsic activity** is greater than zero but less than that of a full agonist [2]. *High affinity with no intrinsic activity* - This describes an **antagonist**, which binds to the receptor with **high affinity** but produces no biological effect (zero intrinsic activity). - An antagonist simply blocks the action of other agonists. *Low affinity with high intrinsic activity* - While binding affinity and intrinsic activity are distinct properties, a drug with **high intrinsic activity** typically produces a strong effect, and low affinity would mean a higher concentration is needed for that effect. This combination does not define a partial agonist. - A full agonist would have **high intrinsic activity**, but affinity can vary. *Low affinity with low intrinsic activity* - A drug with both **low affinity** and **low intrinsic activity** would be a very weak partial agonist, requiring high concentrations to produce only a small effect. - While it technically describes a type of partial agonist, the defining characteristic of a partial agonist is often highlighted by its ability to bind effectively (high affinity) but only partially activate (low intrinsic activity) a receptor.

Question 2: In isolated intestinal smooth muscle preparations, drug X binds to cholinergic receptors and causes relaxation. In the absence of drug X, acetylcholine binds to the same receptors and causes contraction. At low concentrations of drug X, the efficacy (Emax) of acetylcholine is decreased, but its potency (EC50) remains unchanged. At high concentrations of drug X, acetylcholine has no effect. Which of the following statements about drug X is true?

A. A chemical antagonist
B. A physiologic antagonist
C. Non-competitive antagonist (Correct Answer)
D. Competitive antagonist

Explanation: ***Non-competitive antagonist*** - A non-competitive antagonist binds to a site other than the active site (allosteric site) or irreversibly at the active site, reducing the **maximal effect (Emax)** of the agonist without affecting its potency (EC50) at low concentrations [1] - At **low concentrations** of drug X: Emax of acetylcholine decreases while EC50 remains unchanged - characteristic of non-competitive antagonism [2] - At **high concentrations** of drug X: Acetylcholine is completely ineffective as the antagonist fully blocks receptor function - Drug X causes relaxation while acetylcholine causes contraction, both binding to the same cholinergic receptors, with drug X preventing the conformational change needed for acetylcholine's effect *A chemical antagonist* - A chemical antagonist interacts directly with the **agonist molecule itself** to inactivate it through chemical reaction (e.g., protamine neutralizing heparin), rather than binding to a receptor - This mechanism would reduce the amount of available agonist but would not produce the specific pattern of decreased Emax with unchanged EC50 described in the question - The receptor binding described in the question rules out this mechanism *A physiologic antagonist* - A physiologic antagonist acts on a **different receptor system** to produce an opposing physiological effect (e.g., histamine causing bronchoconstriction vs. epinephrine causing bronchodilation via different receptors) - The question explicitly states that drug X binds to the **same cholinergic receptors** as acetylcholine, eliminating physiologic antagonism as the mechanism - Both drugs compete for the same receptor site rather than acting through separate pathways *Competitive antagonist* - A competitive antagonist binds **reversibly** to the same receptor site as the agonist, competing for binding in a concentration-dependent manner [2] - This would **increase EC50** (shift dose-response curve to the right, decreasing potency) while maintaining the **same Emax** if sufficient agonist is added to outcompete the antagonist [1] - The question shows the opposite pattern: **decreased Emax with unchanged EC50**, which is incompatible with competitive antagonism

Question 3: Which of the following statements is correct regarding the given graph?

A. Drug 1 represents agonist and drug 2 represents inverse agonist
B. Drug 3 represents agonist and drug 4 represents inverse agonist
C. Drug 2 represents partial agonist and drug 3 represents inverse agonist
D. Drug 1 represents agonist and drug 4 represents inverse agonist (Correct Answer)

Explanation: ***Drug 1 represents agonist and drug 4 represent inverse agonist*** - **Drug 1** demonstrates maximal efficacy, producing a **supraphysiologic response** above the baseline (100%), characteristic of an **agonist**. - **Drug 4** produces a response **below the baseline** (100%), indicating inhibition of constitutive receptor activity, which is the definition of an **inverse agonist**. *Drug 1 represents agonist and drug 2 represents inverse agonist* - While **Drug 1** is correctly identified as an **agonist** due to its maximal effect above baseline, **Drug 2** is a **partial agonist**, as it produces a submaximal effect above baseline but does not reach the full agonist's efficacy. - **Drug 2** does not reduce the baseline response, so it cannot be an inverse agonist. *Drug 3 represents agonist and drug 4 represents inverse agonist* - **Drug 3** maintains the **baseline response** (at 100%) regardless of concentration, indicating it is a **neutral antagonist** or has no effect, not an agonist. - **Drug 4** is correctly identified as an **inverse agonist** because it reduces the baseline receptor activity. *Drug 2 represents partial agonist and drug 3 represents inverse agonist* - **Drug 2** is correctly identified as a **partial agonist** as it produces an effect above baseline but less than a full agonist. - **Drug 3** is incorrect; it shows no change from baseline (100%), reflecting a **neutral antagonist** or inactive substance, not an inverse agonist which would decrease the baseline response.

Question 4: Which of the following is an example of a prodrug?

A. Primidone
B. Digitoxin
C. Amitriptyline
D. Levodopa (Correct Answer)

Explanation: ***Levodopa is a prodrug that converts to dopamine.*** - A **prodrug** is an inactive precursor of a drug that is converted into its active form within the body. - **Levodopa** is converted to the active neurotransmitter **dopamine** in the brain, making it effective for Parkinson's disease. *Primidone is an anticonvulsant with active metabolites.* - While Primidone has **active metabolites** (phenobarbital and phenylethylmalonamide), the parent drug itself also possesses significant **anticonvulsant activity**, meaning it is not an inactive precursor. - A true prodrug is therapeutically inactive until metabolized. *Digitoxin is a cardiac glycoside that acts directly.* - **Digitoxin** is a cardiac glycoside that directly inhibits the **Na+/K+-ATPase pump**, exerting its therapeutic effect without requiring conversion to an active metabolite. - It does not undergo enzymatic conversion to an active form to produce its primary action. *Amitriptyline is an antidepressant that acts directly.* - **Amitriptyline** is a **tricyclic antidepressant** that directly inhibits the reuptake of norepinephrine and serotonin. - While it is metabolized to an active metabolite (nortriptyline), Amitriptyline itself is **pharmacologically active** as the parent drug.

Question 5: What is the classification of Buprenorphine in terms of its action on opioid receptors?

A. Pure agonist
B. Pure antagonist
C. Partial agonist (Correct Answer)
D. Mixed agonist-antagonist

Explanation: ***Partial agonist*** - **Buprenorphine** acts as a **partial agonist** at the **mu-opioid receptor**, meaning it binds to the receptor and produces some but not all of the effects of full opioid agonists. - This property contributes to its **ceiling effect** for respiratory depression and analgesic effects, making it safer in overdose compared to full agonists. - It has **high receptor affinity** but **lower intrinsic activity** compared to full agonists. *Pure agonist* - A **pure agonist** would fully activate opioid receptors, producing the maximum possible effect at the receptor. - Examples include **morphine** and **fentanyl**, which carry a higher risk of respiratory depression and overdose at higher doses. - These lack the ceiling effect seen with buprenorphine. *Pure antagonist* - A **pure antagonist** would block opioid receptors without activating them, reversing or preventing the effects of agonists. - An example is **naloxone**, which is used to treat opioid overdose by competitive inhibition. *Mixed agonist-antagonist* - **Mixed agonist-antagonists** (e.g., **pentazocine**, **nalbuphine**) act as agonists at some opioid receptors (kappa) and antagonists at others (mu). - Unlike buprenorphine, which is a partial agonist at mu receptors, mixed agonist-antagonists have different actions at different receptor subtypes. - They can precipitate withdrawal in opioid-dependent patients.

Question 6: Therapeutic drug monitoring is done for:

A. Aspirin
B. Heparin
C. Phenytoin (Correct Answer)
D. Metformin

Explanation: ***Phenytoin*** - **Phenytoin** has a **narrow therapeutic window**, meaning the difference between an effective and a toxic dose is small, necessitating close monitoring. - Its **variable absorption** and **nonlinear pharmacokinetics** (saturable metabolism) make individual dosing adjustments critical to maintain therapeutic levels and avoid toxicity. *Aspirin* - **Aspirin** is generally not monitored via plasma levels for its analgesic or antiplatelet effects, as its therapeutic effects are often observed at doses where plasma monitoring is not practical or necessary. - Its primary therapeutic use as an **antiplatelet agent** is evaluated by clinical outcomes rather than drug concentration. *Heparin* - **Heparin** is monitored using coagulation tests like **aPTT (activated partial thromboplastin time)** or anti-Xa levels to assess its anticoagulant effect, not direct drug concentration. - Therapeutic drug monitoring for heparin focuses on its **pharmacodynamic effects** on the clotting cascade rather than its absolute plasma concentration. *Metformin* - **Metformin** has a relatively **wide therapeutic index** and its efficacy is primarily measured by reductions in blood glucose and HbA1c, not by plasma drug concentrations. - It is excreted largely unchanged by the kidneys, and dose adjustments are typically made based on **renal function** and glycemic control.

Question 7: What does the term 'tolerance' refer to in pharmacology?

A. Increased effect of drug on the same dose
B. Decreased effect of drug on the same dose (Correct Answer)
C. Same effect at lower doses
D. No effect

Explanation: ***Decreased effect of drug on the same dose*** - **Tolerance** is a state in which the body's response to a drug is **reduced** over time, requiring higher doses to achieve the same effect. - This phenomenon often develops with **repeated exposure** to a drug, leading to a need for dose escalation. *Increased effect of drug on the same dose* - This describes **sensitization** or **reverse tolerance**, where the body becomes more responsive to the drug over time, which is the opposite of tolerance. - It is not a characteristic feature of pharmacological tolerance. *Same effect at lower doses* - This would imply an **increased sensitivity** to the drug, meaning that less drug is needed to achieve the desired effect. - This is contrary to the definition of tolerance, which requires higher doses for the same effect. *No effect* - While extreme tolerance can lead to a point where a drug has minimal or no clinical effect at standard doses, "no effect" itself is not the primary definition of tolerance. - Tolerance refers to the gradual **reduction in effect**, rather than an immediate absence of effect.

Question 8: In the mitogen activated protein kinase pathway, the activation of RAS is counteracted by

A. Inositol triphosphate
B. GTPase activating protein (Correct Answer)
C. Phosphatidyl inositol
D. Protein kinase C

Explanation: ***GTPase activating protein*** - **GTPase Activating Proteins (GAPs)** facilitate the hydrolysis of **GTP bound to RAS** to GDP, converting active RAS back to its inactive state. - This inactivation is crucial for turning off the downstream signaling of the **MAPK pathway** and preventing uncontrolled cell proliferation. *Inositol triphosphate* - **Inositol triphosphate (IP3)** is a secondary messenger that triggers the release of **intracellular calcium** from the endoplasmic reticulum. - It is involved in various signaling pathways, but its primary role is not to directly counteract RAS activation. *Phosphatidyl inositol* - **Phosphatidylinositol (PI)** is a component of cell membranes and can be phosphorylated to produce various **phosphatidylinositol phosphates (PIPs)**, like **PIP2** and **PIP3**. - These molecules act as docking sites for signaling proteins but do not directly inactivate RAS. *Protein kinase C* - **Protein kinase C (PKC)** is a family of enzymes involved in signal transduction, typically activated by **diacylglycerol (DAG)** and calcium. - It phosphorylates various proteins, mediating diverse cellular responses, but it does not directly counteract the activation of RAS.

Question 9: What do A and B represent in the curve shown below?

A. A= Median effective dose, B= Median lethal dose (Correct Answer)
B. A= Therapeutic index, B= Median efficacy
C. A= Median lethal dose, B= Median effective dose
D. A= Median efficacy, B= Therapeutic index

Explanation: ***A= Median effective dose, B= Median lethal dose*** - **A** corresponds to the **median effective dose (ED50)**, which is the dose that produces a therapeutic effect in 50% of the population - The purple curve represents the dose-response for efficacy; at A, 50% of individuals are responding effectively - **B** corresponds to the **median lethal dose (LD50)**, which is the dose that is lethal to 50% of the population - The red curve represents the dose-response for toxicity/lethality; at B, 50% of individuals are experiencing a lethal outcome *A= Therapeutic index, B= Median efficacy* - The **therapeutic index** is a ratio (LD50/ED50), not a specific dose represented on the x-axis - **Median efficacy** is not a standard pharmacological term to represent a point on a dose-response curve; rather, efficacy refers to the maximal effect a drug can produce *A= Median lethal dose, B= Median effective dose* - This option reverses the correct identification of A and B - **Median effective dose (ED50)** is typically expected at lower doses, while **median lethal dose (LD50)** is at higher doses, indicating toxicity - In the provided graph, the curve for A occurs at a much lower dose range than the curve for B, making it the effective dose, not the lethal dose *A= Median efficacy, B= Therapeutic index* - **Median efficacy** is not a specific dose value represented this way on a dose-response curve - The **therapeutic index** is a ratio, not a dose point on the graph

Question 10: Capsaicin acts on ______

A. Vanilloid receptor (Correct Answer)
B. Capsaicoid receptor
C. AMPA receptor
D. NMDA receptor

Explanation: ***Vanilloid receptor*** - Capsaicin is the active component of chili peppers and exerts its effects primarily through activation of the **transient receptor potential vanilloid 1 (TRPV1) receptor**, also known as the vanilloid receptor. - Activation of **TRPV1** by capsaicin leads to an influx of **calcium ions**, causing depolarization and firing of nociceptive neurons, which is perceived as burning pain. *Capsaicoid receptor* - This term is **not a recognized scientific receptor name** for capsaicin's primary target. - It might be a colloquial or misnomer derived from the mechanism of action of capsaicin. *AMPA receptor* - **AMPA receptors** are **ionotropic glutamate receptors** that mediate fast synaptic transmission in the central nervous system. - They are primarily involved in learning, memory, and synaptic plasticity, not directly activated by capsaicin. *NMDA receptor* - **NMDA receptors** are another type of **ionotropic glutamate receptor** that plays a crucial role in synaptic plasticity and learning. - Although also involved in pain processing, they are distinct from the **TRPV1 receptor** and are not directly activated by capsaicin.

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free